# Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

> **NCT02492750** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 14 (actual)

## Conditions studied

- Indolent Plasma Cell Myeloma
- Plasma Cell Myeloma
- Smoldering Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Anakinra
- **DRUG:** Dexamethasone
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02492750
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2019-06-05
- **Final completion:** 2019-09-13
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2020-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02492750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02492750, "Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02492750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*